Original Research
This article assesses the effectiveness and tolerability profile of vericiguat in clinical practice in patients with heart failure with reduced ejection fraction and an implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular arrhythmias.
Corrigendum
The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R, Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. Drugs Context. 2024;13:2023-8-1. https://doi.org/10.7573/dic.2023-8-1
Review
Heart failure (HF) represents a major healthcare problem, reaching epidemic figures worldwide. This article provides an update on the vulnerable period of HF with reduced ejection fraction (HFrEF) and recommendations are given regarding the management of HF during this phase.
Review
This review aims to expose the multiple approaches for treatment of patients with diuretic resistance and the importance of intravascular volume expansion in the response to therapy.
Review
The authors provide a comprehensive overview of clinicians’ adherence to heart failure guidelines in a specialized real-life setting, particularly regarding use and optimization of guideline-derived medical therapies, as well as the implementation of more recent agents. They seek potential explanations for suboptimal treatment and its impact on patient outcomes.
